Ticagrelor in Remote Ischemic Preconditioning Study
Status:
Completed
Trial end date:
2018-01-17
Target enrollment:
Participant gender:
Summary
Remote ischemic preconditioning (RIPC) reduces periprocedural myocardial injury (PMI) after
percutaneous coronary intervention (PCI) through various pathways, including an
adenosine-triggered pathway. Ticagrelor inhibits adenosine uptake, thus may potentiate the
effects of RIPC.
This randomized trial tested the hypothesis that ticagrelor potentiates the effect of RIPC
and reduces PMI, as assessed by post-procedural troponin release